Remsleep Holding Stock Price, News & Analysis

RemSleep Holdings (OTC PINK: RMSL) announced its uplisting to OTCQB® status, enhancing investor benefits including improved reporting standards and greater access to analyst coverage. This uplisting is expected to increase liquidity, market visibility, and shareholder value. CEO Tom Wood emphasized the significance of this milestone, pointing to upcoming FDA filings for their DeltaWave Nasal Pillow Mask and plans for additional CPAP devices. The company aims to transition from a pre-revenue state to a profitable public entity.

RemSleep Holdings Inc (OTC PINK: RMSL) recently addressed shareholders regarding its S-1 filing dated June 15, 2022. The company clarified that the S-1 was precautionary, aimed at providing a safety net amid rising inflation and economic challenges, not an immediate necessity. They reaffirmed goals of increasing revenue from CPAP agreements, obtaining FDA approval for the DeltaWave Nasal Pillow Mask, and expanding their product line. The company has decided to terminate the S-1 filing and has no current plans to raise capital or increase share counts.

RemSleep Holdings (OTC PINK: RMSL) recently submitted its application for OTCQB® status, aiming to enhance its market position for obstructive sleep apnea treatment. The decision is expected in 3-4 weeks. This uplisting promises improved transparency, compliance, and access to a wider investor base. CEO Tom Wood expressed confidence in obtaining FDA approval for their DeltaWave CPAP nasal interface and transitioning to a profitable status. The OTCQB® is recognized for better investor benefits compared to OTC Pink, and it has historically increased liquidity and visibility for companies.

RemSleep Holdings (OTC PINK: RMSL) announced a regulatory update regarding its DeltaWave device, which will now undergo a 510K review as an implantable device. This requires additional testing, prompting the company to withdraw its current application. The FDA has acknowledged that existing test results can support the new submission. The company remains optimistic about timely approval and plans to also submit a 510K for its next-generation Nasal Pillows interface. Additionally, the OTCQB application is nearing completion, with ongoing updates promised to shareholders.

RemSleep Holdings (OTC PINK: RMSL) has responded to the FDA's Additional Information request regarding its 510(k) application for the DeltaWave device, a nasal mask CPAP interface. This pivotal submission is expected to enhance the commercialization of the DeltaWave, known for its comfort and adequate airflow, potentially disrupting the sleep apnea market. The company anticipates an FDA decision in around 30 days and is committed to keeping shareholders informed on progress.

RemSleep Holdings (OTC PINK: RMSL) issued a corporate update highlighting challenges with its DeltaWave device's FDA 510k submission. The company failed a cytotoxicity retest due to faults by a third-party lab, prompting a commitment to retest with a new lab. Despite this setback, the company is advancing with new distribution agreements for CPAP machines, with FDA-approved devices unaffected by current chip shortages. They signed a three-year lease for a larger facility and are working towards OTCQB tier designation to enhance operations.

RemSleep Holdings (OTC PINK: RMSL) has secured an agreement with an overseas manufacturer to import nasal CPAP machines amidst a significant shortage in the U.S. A first order of 1,500 units is expected to ship by mid-April, with plans for presales to boost revenues. This move aims to alleviate the ongoing CPAP device scarcity resulting from recent recalls and global supply chain issues. To support growth, RemSleep is relocating to a larger facility and enhancing its marketing efforts. The company addresses the needs of the 22 million Americans suffering from sleep apnea.

RemSleep Holdings (OTC PINK: RMSL) announced a strategic partnership with Preya Co and MCAP Mediawire to enhance communication with shareholders and strengthen their outreach efforts. This move comes in anticipation of the expected DeltaWave 510k approval and market release, addressing the high demand from both the public and medical community. CEO Tom Wood emphasized the importance of maintaining open communication with investors to add value. Preya Co offers expertise in investor relations, while MCAP Mediawire provides robust news distribution services.